Can a cancer drug stop myeloma before it starts?

NCT ID NCT02316106

Completed Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tested three different schedules of the drug daratumumab in 123 people with smoldering multiple myeloma, a condition that often progresses to active multiple myeloma. The goal was to see how well each schedule controlled the disease and led to complete responses. Researchers measured response rates and how many patients progressed or died.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: daratumumab
What this could lead to: If successful, this could help delay or prevent smoldering multiple myeloma from becoming active multiple myeloma, potentially reducing the need for more intensive treatments.
What could go wrong: This is a phase 2 trial with only 123 participants, so results are preliminary. Daratumumab may cause side effects like infusion reactions or infections, and not all patients may benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma Smoldering Multiple Myeloma smoldering plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Study site

Little Rock, Arkansas, United States
Study site

Jacksonville, Florida, United States
Study site

West Palm Beach, Florida, United States
Study site

Atlanta, Georgia, United States
Study site

Boston, Massachusetts, United States
Study site

Ann Arbor, Michigan, United States
Study site

St Louis, Missouri, United States
Study site

Hackensack, New Jersey, United States
Study site

New York, New York, United States
Study site

Chapel Hill, North Carolina, United States
Study site

Cincinnati, Ohio, United States
Study site

Columbus, Ohio, United States
Study site

Philadelphia, Pennsylvania, United States
Study site

Nashville, Tennessee, United States
Study site

Seattle, Washington, United States
Study site

Box Hill, Australia
Study site

Concord, Australia
Study site

Melbourne, Australia
Study site

Woodville South, Australia
Study site

Calgary, Alberta, Canada
Study site

Edmonton, Alberta, Canada
Study site

Toronto, Ontario, Canada
Study site

Brno, Czechia
Study site

Hradec Králové, Czechia
Study site

Prague, Czechia
Study site

Lille, France
Study site

Nantes, France
Study site

Paris, France
Study site

Pierre-Bénite, France
Study site

Rennes, France
Study site

Berlin, Germany
Study site

Chemnitz, Germany
Study site

Essen, Germany
Study site

Heidelberg, Germany
Study site

Mainz, Germany
Study site

München, Germany
Study site

Tübingen, Germany
Study site

Würzburg, Germany
Study site

Haifa, Israel
Study site

Jerusalem, Israel
Study site

Petah Tikva, Israel
Study site

Tel Aviv, Israel
Study site

Amsterdam, Netherlands
Study site

Rotterdam, Netherlands
Study site

Utrecht, Netherlands
Study site

Nizhny Novgorod, Russia
Study site

Petrozavodsk, Russia
Study site

Ryazan, Russia
Study site

Saint Petersburg, Russia
Study site

Ankara, Turkey (Türkiye)
Study site

Antalya, Turkey (Türkiye)
Study site

Izmir, Turkey (Türkiye)
Study site

Samsun, Turkey (Türkiye)
Study site

Cardiff, United Kingdom
Study site

Nottingham, United Kingdom
Study site

Southampton, United Kingdom
Study site

Surrey, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.